BMS Presents Data from Multiple New Studies at IDWeek 2014 Showcasing Continued Innovation in Virology

Bristol-Myers Squibb Company (BMS) has announced that ten abstracts have been accepted for presentation at IDWeek 2014, which is taking place in Philadelphia, PA, 8–12 October 2014. The breadth of data being presented highlights BMS’s commitment to discover, develop and deliver innovative medicines that help patients prevail over chronic viral diseases.

Highlights include

• A 24 week sub-group analysis investigating the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced patients infected with HIV-1, as well as a 24 week safety profile analysis in this group. BMS-663068 is an investigational prodrug of an attachment inhibitor with a unique mechanism of action that prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell.

• A series of data presentations investigating the use of daclatasvir in multiple treatment regimens with other antiviral medicines and among varied patient groups and HCV genotypes. Daclatasvir is an investigational NS5A replication complex inhibitor that has shown high antiviral potency and pan-genotypic activity across HCV genotypes (in vitro).

“The compelling body of data presented at this year’s IDWeek underscore Bristol-Myers Squibb’s ongoing commitment to pioneering scientific innovation that investigates the significant unmet medical needs of those living with chronic viral diseases including HIV and HCV,” said Douglas Manion, M.D., Head of Specialty Development, Bristol-Myers Squibb. “We aim to bring to market treatment options that will improve health outcomes for a diverse range of HIV and HCV patients, including treatment-experienced HIV patients in search of new options, and HCV patients with difficult-to-treat disease.”